AQST - Company ID 0001398733
The table below shows Aquestive Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $44.55M | $57.56M | $50.58M | $47.68M | $50.83M | $45.85M |
| Cost of revenue | $18.55M | $17.87M | $20.83M | $19.39M | - | $12.96M |
| Gross profit | - | - | - | - | - | - |
| R&D | $17.19M | $20.28M | $13.10M | $17.48M | $17.05M | $19.89M |
| SG&A |
Aquestive Therapeutics, Inc. reported annual revenue of $44.55M for fiscal year 2025. That is down 22.6% from $57.56M in fiscal 2024. Over the 9 fiscal years shown, annual revenue declined from $66.92M (FY 2017) to $44.55M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $79.85M |
| $50.18M |
| $31.75M |
| $52.88M |
| $53.48M |
| $55.89M |
| Operating income | -$71.05M | -$30.77M | -$15.10M | -$42.07M | -$34.68M | -$42.89M |
| Income tax | $0.00 | -$14.00K | $245.00K | $0.00 | $0.00 | $0.00 |
| Net income | -$83.78M | -$44.14M | -$7.87M | -$54.41M | -$70.54M | -$55.78M |
| EPS (diluted) | -$0.78 | -$0.51 | -$0.13 | -$1.12 | -$1.85 | -$1.66 |